Mostrar el registro sencillo del ítem
CYP450 and Its Implications in the Clinical Use of Antipsychotic Drugs
dc.contributor.author | Mora, Fernando | |
dc.contributor.author | Molina Martín, Juan de Dios | |
dc.contributor.author | Zubillaga, Elena | |
dc.contributor.author | López-Muñoz, F. | |
dc.contributor.author | Álamo González, C | |
dc.date.accessioned | 2018-07-09T11:34:09Z | |
dc.date.available | 2018-07-09T11:34:09Z | |
dc.date.issued | 2015-05-25 | |
dc.identifier.citation | Mora F, Molina JD, Zubillaga E, López-Muñoz F, Álamo C (2015) CYP450 and Its Implications in the Clinical Use of Antipsychotic Drugs. Clin Exp Pharmacol 5: 176. doi:10.4172/2161-1459.1000176 | es |
dc.identifier.issn | 2161-1459 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12020/777 | |
dc.description.abstract | Polypharmacy implies a high potential for drug-drug interactions. The capacity of the cytochrome P450 enzyme system involved in the metabolism of psychoactive drugs differs greatly, which leads to variable drug elimination rates and inter-subject differences in serum drug concentrations. Polymorphisms in genes coding for CYP450 enzymes contribute to this inter-subject variability. Therapeutic response and adverse effects vary among patients treated with the same dose of a certain drug. Polypharmacy, comorbidity and the use of certain substances (grapefruit juice, caffeine and tobacco) increase the chances of clinically relevant interactions in a psychotic patient. Choosing drugs with low interaction potential seems to be the best strategy to prevent clinically relevant interactions particularly in elderly, polymedicated, oncologic and HIV patients. | es |
dc.language.iso | en | es |
dc.publisher | Jun-Ping Liu | es |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.title | CYP450 and Its Implications in the Clinical Use of Antipsychotic Drugs | es |
dc.type | article | es |
dc.identifier.doi | 10.4172/2161-1459.1000176 | |
dc.issue.number | 3 | es |
dc.journal.title | Journal of oJ Clinical and Experimental Pharmacology | es |
dc.page.initial | 1 | es |
dc.page.final | 4 | es |
dc.rights.accessRights | openAccess | es |
dc.subject.area | Psicología | es |
dc.subject.keyword | CYP450 | es |
dc.subject.keyword | Drug interactions | es |
dc.subject.keyword | Antipsychotic | es |
dc.subject.keyword | Pharmacokinetic | es |
dc.subject.keyword | Polypharmacy | es |
dc.subject.unesco | 3201.05 Psicología Clínica | es |
dc.subject.unesco | 3209 Farmacología | es |
dc.volume.number | 5 | es |